Protocol Ledger

NCT05578976 · Phase III · ACTIVE NOT RECRUITING

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in

Interventional Phase III clinical trial protocol NCT05578976 sponsored by Genmab in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-02-08 Enrollment: 900 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05578976
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)900 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05578976
Protocol FieldVerified Registry Value
NCT IdentifierNCT05578976
Consolidated Lead SponsorGenmab
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment900 participants (ESTIMATED)
Registered Start Date2023-02-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI